United Therapeutics Corporation $UTHR Stock Holdings Lessened by Vinva Investment Management Ltd

Vinva Investment Management Ltd cut its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 36.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 24,964 shares of the biotechnology company’s stock after selling 14,502 shares during the period. Vinva Investment Management Ltd’s holdings in United Therapeutics were worth $10,592,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AXQ Capital LP grew its holdings in shares of United Therapeutics by 495.4% during the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after purchasing an additional 3,235 shares during the last quarter. AE Wealth Management LLC raised its position in shares of United Therapeutics by 396.3% during the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 3,424 shares during the period. Great Lakes Advisors LLC lifted its holdings in shares of United Therapeutics by 194.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after purchasing an additional 2,975 shares during the last quarter. Optimize Financial Inc acquired a new position in United Therapeutics during the 3rd quarter valued at approximately $444,000. Finally, Simplify Asset Management Inc. acquired a new position in United Therapeutics during the 3rd quarter valued at approximately $8,351,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $483.16, for a total value of $4,010,228.00. Following the completion of the sale, the executive vice president directly owned 36,844 shares of the company’s stock, valued at approximately $17,801,547.04. This represents a 18.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christopher Causey sold 1,000 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $520.00, for a total transaction of $520,000.00. Following the completion of the transaction, the director owned 4,190 shares of the company’s stock, valued at $2,178,800. This trade represents a 19.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 329,684 shares of company stock worth $160,260,377 in the last three months. Insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of a number of recent research reports. Wells Fargo & Company upped their price objective on United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 26th. Oppenheimer boosted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. UBS Group upped their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday. TD Cowen increased their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Finally, HC Wainwright lifted their price objective on shares of United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $539.00.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and kept a Buy rating — a notable analyst endorsement implying material upside that could attract buyers. Read More.
• Neutral Sentiment: Multiple sell‑side firms have recently increased targets and reiterated Buy/outperform views (Oppenheimer, HC Wainwright, TD Cowen); consensus remains a “Moderate Buy” with a mid‑range price target, supporting a constructive medium‑term thesis. Read More.
• Negative Sentiment: A wave of insider selling this week is pressuring sentiment: CEO Martine Rothblatt sold 9,500 shares (~$4.65M), and several directors/executives (Ray Kurzweil, Paul Mahon, Tommy G. Thompson and others) also sold blocks at roughly $483–$490 per share. These large, concentrated disposals can prompt near‑term weakness even if insiders retain stakes. Read More. Read More.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $478.16 on Monday. The stock has a market cap of $20.96 billion, a price-to-earnings ratio of 17.14, a PEG ratio of 1.72 and a beta of 0.84. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $537.19. The business has a fifty day moving average of $482.51 and a 200-day moving average of $454.28.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the business earned $6.19 earnings per share. On average, equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.